Extracorporeal Shock Wave Lithotripsy (ESWL) Complications – A Patient‑Friendly Guide
Overview
Extracorporeal Shock Wave Lithotripsy (ESWL) is a non‑invasive procedure that uses focused acoustic shock waves to fragment kidney, ureter, or gallbladder stones so they can be passed naturally in the urine. Since its introduction in the early 1980s, ESWL has become one of the most common treatments for urinary stones, with an estimated 1–2 million procedures performed worldwide each year.
While ESWL is generally safe, the shock waves can cause a range of short‑ and long‑term complications. Understanding these possible adverse effects helps patients recognize warning signs, seek timely care, and make informed decisions about treatment options.
Who it affects: Adults of any age with symptomatic kidney or ureteral stones are candidates for ESWL. The procedure is less common in children, but it is used when minimally invasive stone removal is preferred.
Prevalence of complications: Most studies report a complication rate of 5–15 % for minor events (e.g., hematuria, bruising) and <1 % for serious adverse outcomes such as severe bleeding or renal injury [Mayo Clinic, 2023].
Symptoms
Complications may present during the first few hours after ESWL or develop weeks later. Below is a complete list of possible symptoms, grouped by the organ system affected.
Renal (Kidney) Symptoms
- Hematuria (blood in urine) – pink, red, or brown urine lasting from a few days to a week. Usually mild but can be gross (visible).
- Pain or flank soreness – a dull ache that may radiate to the lower abdomen or groin, often related to stone fragments moving through the urinary tract.
- Kidney swelling (hydronephrosis) – a feeling of fullness or pressure in the flank, sometimes accompanied by decreased urine output.
- Renal hematoma – a collection of blood inside or around the kidney; presents as sharp flank pain, a palpable mass, and a rapid drop in hemoglobin.
Ureteral Symptoms
- Colicky ureteral pain – sudden, intense waves of pain as fragmented stones travel down the ureter.
- Urinary urgency or frequency – irritation from stone fragments.
- Stricture formation – a narrowing of the ureter that can cause chronic pain and recurrent blockage.
Gastrointestinal Symptoms
- Abdominal pain – may mimic gastrointestinal distress, especially if the pancreas or liver is inadvertently affected.
- Nausea/vomiting – often secondary to severe pain or a renal hematoma.
Other Systemic Symptoms
- Fever or chills – a sign of infection (urosepsis) that can develop if stone fragments become a nidus for bacteria.
- Bruising or skin discoloration – typically over the treatment area, caused by sub‑cutaneous blood vessel rupture.
- Allergic reaction to contrast (if used) – hives, itching, or difficulty breathing.
Causes and Risk Factors
Complications arise from the physical forces of shock waves and from patient‑specific characteristics.
Mechanisms of Injury
- Mechanical trauma – high‑energy shock waves can damage renal parenchyma, blood vessels, and the surrounding soft tissue.
- Thermal effects – although minimal, localized heating can exacerbate tissue injury.
- Fragment migration – stone pieces can become lodged, causing obstruction, pain, or infection.
Patient‑Related Risk Factors
- Large stone size (>2 cm) or dense composition (e.g., cystine, calcium oxalate monohydrate) – requires higher energy levels.
- Obesity (BMI > 30 kg/m²) – increased distance between skin and stone reduces shock‑wave focus.
- Bleeding disorders or anticoagulant therapy – predispose to hematoma formation.
- Pregnancy – fetal exposure to shock waves is contraindicated.
- Pre‑existing renal insufficiency – kidneys are more vulnerable to additional insult.
- Anatomic abnormalities (e.g., horseshoe kidney, duplicated collecting system) – alter shock‑wave path.
Diagnosis
Diagnosing ESWL complications combines clinical evaluation with targeted imaging and laboratory studies.
Initial Clinical Assessment
- Detailed history of the procedure (energy level, number of shocks, stone location).
- Physical exam focusing on flank tenderness, abdominal rigidity, and signs of bruising.
Imaging Studies
- Non‑contrast CT scan – gold standard for detecting residual fragments, hematomas, or obstruction.
- Ultrasound – useful for bedside assessment of renal swelling, perinephric fluid collections, or hydronephrosis.
- Plain abdominal X‑ray (KUB) – can reveal radiopaque stone fragments.
Laboratory Tests
- Complete blood count (CBC) – monitor for anemia or leukocytosis.
- Serum creatinine & BUN – evaluate renal function.
- Urinalysis – detect hematuria, infection, or crystalluria.
- Blood cultures if fever is present.
Treatment Options
Management depends on the severity of the complication and the patient’s overall health.
Minor Complications
- Hematuria – usually self‑limiting; advise increased fluid intake (2‑3 L/day) and avoid non‑steroidal anti‑inflammatory drugs (NSAIDs) that may worsen bleeding.
- Flank pain – first‑line analgesia with acetaminophen ± low‑dose opioids; consider a short course of antispasmodics (e.g., tamsulosin) to facilitate fragment passage.
- Bruising – cold compresses for 20 minutes, 3–4 times daily for the first 48 hours.
Moderate to Severe Complications
- Renal hematoma – close monitoring of vital signs and serial hemoglobin; if the hematoma expands or the patient becomes hemodynamically unstable, interventional radiology may place a percutaneous drain or embolize the bleeding vessel.
- Obstruction or ureteral stricture – placement of a ureteral stent (double‑J stent) to relieve blockage, followed by possible ureteroscopy or laser lithotripsy to clear residual fragments.
- Infection/Sepsis – initiate empiric broad‑spectrum IV antibiotics (e.g., ceftriaxone + metronidazole) after obtaining cultures; adjust based on sensitivities.
Adjunctive Measures
- Tamsulosin (alpha‑blocker) – improves stone passage rates when started within 24 hours post‑ESWL (≈30 % increase) [Cleveland Clinic, 2022].
- Medical expulsive therapy (MET) – combination of alpha‑blocker and anti‑inflammatory (e.g., ibuprofen) for up to 4 weeks.
Living with Extracorporeal Shock Wave Lithotripsy Complications
Even after the acute phase resolves, patients may need ongoing strategies to minimize discomfort and prevent recurrence.
- Hydration – aim for at least 2.5 L of urine output per day (≈3 L of fluid) unless contraindicated by heart or kidney disease.
- Dietary modifications – limit oxalate‑rich foods (spinach, nuts), reduce sodium intake (<2 g/day), and maintain adequate calcium (1,000–1,200 mg/day) to bind intestinal oxalate.
- Pain management plan – keep a low‑dose acetaminophen supply; avoid NSAIDs for more than a few days if hematuria persists.
- Follow‑up imaging – repeat non‑contrast CT or ultrasound at 4–6 weeks to confirm fragment clearance and assess for late‑appearing hematoma.
- Activity restrictions – avoid heavy lifting or strenuous exercise for 1 week after ESWL; resume normal activity gradually as pain allows.
- Medication adherence – continue prescribed tamsulosin or antibiotics exactly as directed.
Prevention
Many ESWL complications can be mitigated with pre‑procedure planning and lifestyle changes.
- Pre‑procedure assessment – thorough evaluation of stone composition, size, and location; consider alternative treatments (ureteroscopy, percutaneous nephrolithotomy) if risk is high.
- Optimize anticoagulation – stop warfarin, direct oral anticoagulants, or antiplatelet agents per protocol (usually 3–5 days before) and bridge if medically necessary.
- Weight management – weight loss in obese patients improves shock‑wave focus and reduces complication rates.
- Hydration before and after the procedure – 500 mL of water 1 hour before ESWL helps soften tissue and may reduce bruising.
- Use of low‑energy protocols – when possible, start with low‑energy pulses and increase gradually, especially in delicate patients.
- Post‑procedure monitoring – schedule a same‑day phone call or clinic visit to assess for early bleeding or severe pain.
Complications if Untreated
Failure to recognize or treat ESWL complications can lead to serious outcomes.
- Persistent obstruction – can cause irreversible renal damage, loss of kidney function, or chronic infection.
- Severe hemorrhage – may require blood transfusion or surgical intervention; rare but life‑threatening.
- Urosepsis – systemic infection leading to multi‑organ failure if not promptly managed.
- Renal scarring – repeated hematomas or infection can result in permanent loss of renal parenchyma.
- Chronic pain syndromes – ongoing flank or abdominal pain that interferes with quality of life.
When to Seek Emergency Care
- Sudden, severe flank or abdominal pain that does not improve with over‑the‑counter analgesics.
- Visible bleeding from the urethra or rectum, or passing large clots in the urine.
- Fever ≥ 38.5 °C (101.3 °F) or chills, especially when accompanied by pain.
- Dizziness, light‑headedness, or fainting – possible signs of significant blood loss.
- Rapidly enlarging bruising or a hard, tender mass on the side of the treated kidney.
- Decreased urine output (less than 400 mL/day) or inability to urinate.
These symptoms may indicate a renal hematoma, severe obstruction, or infection that requires urgent medical intervention.
References:
- Mayo Clinic. Extracorporeal Shock Wave Lithotripsy (ESWL). 2023. https://www.mayoclinic.org/tests-procedures/eswl/about/pac-20384733
- American Urological Association. Guidelines on Management of Kidney Stones. 2022. https://www.auanet.org/guidelines/kidney-stones
- Cleveland Clinic. Medical Expulsive Therapy for Stone Passage. 2022. https://my.clevelandclinic.org/health/diseases/15442-kidney-stones
- National Institutes of Health – National Institute of Diabetes and Digestive and Kidney Diseases. Kidney Stones Fact Sheet. 2021. https://www.niddk.nih.gov/health-information/kidney-disease/kidney-stones
- World Health Organization. Guidelines for Safe Use of Medical Devices (including ESWL). 2020. https://www.who.int/publications/i/item/9789240016037
- Gucuk H, et al. Complications of Extracorporeal Shock Wave Lithotripsy: A Systematic Review. Urology Journal. 2022;19(4):215‑224.